Repositioning Candidate Details
| Candidate ID: | R1092 |
| Source ID: | DB06757 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Manganese |
| Synonyms: | -- |
| Molecular Formula: | Mn |
| SMILES: | [Mn++] |
| Structure: |
|
| DrugBank Description: | Manganese is a transition metal with a molar mass of 54.94g/mol. Manganese is considered critical for human health, and plays important roles in development, metabolism, and the antioxidant system. That said, excessive manganese intake is associated with manganism, a neurodegenerative disorder that causes dopaminergic neuronal death and parkinsonian-like symptoms. |
| CAS Number: | 7439-96-5 |
| Molecular Weight: | 54.938 |
| DrugBank Indication: | Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial; Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial; TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; Arginase-1; Serotransferrin |
| Inclusion Criteria: | Target associated |
